GLP-1 RAs show potential benefits for diabetic retinopathy and macular degeneration through anti-inflammatory and neuroprotective mechanisms, but their effects on glaucoma and NAION warrant careful monitoring.
Benefits AND risksGLP-1 drugs may protect the retina but have potential concerns for intraocular pressure and optic nerve health
What the researchers found
GLP-1 RAs show potential retinal benefits (DR, AMD) through anti-inflammatory/neuroprotective mechanisms, but effects on glaucoma (IOP) and NAION risk require monitoring, creating a nuanced ocular safety-benefit profile.
Why it matters
Millions of GLP-1 drug users are at risk for diabetic eye disease. Understanding both benefits and risks guides ophthalmologic management.
How the study worked
Review of preclinical and clinical evidence on GLP-1 RA effects across glaucoma, diabetic retinopathy, age-related macular degeneration, and NAION.
What this study cannot tell us
Most ocular evidence is preclinical or observational. No dedicated ophthalmologic RCTs for GLP-1 drugs. NAION association remains uncertain.
How to read the evidence
Review of mixed preclinical and clinical evidence. Benefits are biologically plausible; risks are preliminary signals.
When this study was published
Published in 2025.
The bigger picture
GLP-1 receptors are expressed throughout the eye, suggesting these drugs interact with ocular biology in complex ways that are only beginning to be understood.
Questions still open
- Should ophthalmologic screening be standard for long-term GLP-1 drug users?
- Could topical GLP-1 delivery provide ocular benefits without systemic effects?
- Is the NAION risk real or confounded by diabetes itself?
Common questions
Can GLP-1 drugs affect my eyes?
Should I be worried about my eyes on Ozempic?
Read the original research
Glucagon-like Peptide-1 Receptor Agonists and Ocular Disease: Mechanisms, Evidence and Therapeutic Perspectives.
International journal of molecular sciences, 27(3)
Citation
Gong, Xiaoming; Örge, Faruk H. (2026). Glucagon-like Peptide-1 Receptor Agonists and Ocular Disease: Mechanisms, Evidence and Therapeutic Perspectives.. International journal of molecular sciences, 27(3). https://doi.org/10.3390/ijms27031432